HK1111414A1 - Substituted 2h-1,3-benzoxazin-4(3h)-ones - Google Patents

Substituted 2h-1,3-benzoxazin-4(3h)-ones

Info

Publication number
HK1111414A1
HK1111414A1 HK08102004.2A HK08102004A HK1111414A1 HK 1111414 A1 HK1111414 A1 HK 1111414A1 HK 08102004 A HK08102004 A HK 08102004A HK 1111414 A1 HK1111414 A1 HK 1111414A1
Authority
HK
Hong Kong
Prior art keywords
benzoxazin
ones
substituted
Prior art date
Application number
HK08102004.2A
Other languages
English (en)
Inventor
Robert M Scarborough
Meenakshi S Venkatraman
Xiaoming Zhang
Anjali Pandey
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of HK1111414A1 publication Critical patent/HK1111414A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08102004.2A 2004-09-29 2008-02-22 Substituted 2h-1,3-benzoxazin-4(3h)-ones HK1111414A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61456404P 2004-09-29 2004-09-29
PCT/US2005/034246 WO2006039212A2 (en) 2004-09-29 2005-09-26 Substituted 2h-1,3-benzoxazin-4(3h)-ones

Publications (1)

Publication Number Publication Date
HK1111414A1 true HK1111414A1 (en) 2008-08-08

Family

ID=36142983

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08102004.2A HK1111414A1 (en) 2004-09-29 2008-02-22 Substituted 2h-1,3-benzoxazin-4(3h)-ones

Country Status (14)

Country Link
US (1) US7205296B2 (xx)
EP (1) EP1812429A4 (xx)
JP (1) JP2008514703A (xx)
KR (1) KR20070064356A (xx)
CN (1) CN101031565B (xx)
AU (1) AU2005292314B2 (xx)
BR (1) BRPI0516181A (xx)
CA (1) CA2581638A1 (xx)
HK (1) HK1111414A1 (xx)
IL (1) IL182180A0 (xx)
MX (1) MX2007003836A (xx)
NZ (1) NZ554211A (xx)
WO (1) WO2006039212A2 (xx)
ZA (1) ZA200702688B (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US7740693B2 (en) 2007-10-01 2010-06-22 Honeywell International Inc. Organic fluorescent sulfonyl ureido benzoxazinone pigments
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
CA2853439A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
SG11201408284VA (en) * 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
US9469654B2 (en) 2012-09-27 2016-10-18 Portola Pharmaceuticals, Inc. Bicyclic oxa-lactam kinase inhibitors
US9550775B2 (en) 2013-03-14 2017-01-24 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
MX2016006936A (es) 2013-11-27 2016-10-05 Genentech Inc Benzamidas sustituidas y metodos para usarlas.
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
RU2719422C2 (ru) 2014-08-04 2020-04-17 Нуэволюшон А/С Необязательно конденсированные гетероциклил-замещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US10538487B2 (en) 2015-02-16 2020-01-21 The University Of Queensland Sulfonylureas and related compounds and use of same
BR112017024853A2 (pt) 2015-05-22 2018-08-07 Genentech Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
AU2017347549A1 (en) 2016-10-17 2019-05-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
HRP20220195T1 (hr) 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
EP3707134A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
TW202000651A (zh) 2018-02-26 2020-01-01 美商建南德克公司 治療性組成物及其使用方法
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
MX2021012418A (es) 2019-04-09 2021-11-12 Nuvation Bio Inc Compuestos heterociclicos y sus usos.
JP7450980B2 (ja) * 2019-12-10 2024-03-18 シャンハイ ジムン バイオファーマ，インコーポレーテッド 神経保護効果を有する化合物およびその調製方法と用途
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
FR2702477B1 (fr) * 1993-03-08 1995-04-28 Synthelabo Dérivés de benzoxazine, leur préparation et leur application en thérapeutique.
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AU2219599A (en) 1998-01-15 1999-08-02 Millennium Pharmaceuticals, Inc. Platelet adp receptor inhibitors
PT1087775E (pt) * 1998-06-17 2005-11-30 Bristol Myers Squibb Co Prevencao de enfarte cerebral por administracao de uma combinacao de farmacos antiplaquetarios bloqueadores de receptores de adp e anti-hipertensivos
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2002210982A1 (en) * 2000-11-01 2002-05-15 Yamanouchi Pharmaceutical Co..Ltd. Method of screening antiplatelet
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
JPWO2004052871A1 (ja) * 2002-12-06 2006-04-13 東レ株式会社 ベンゾモルホリン誘導体
EP1667989A4 (en) * 2003-10-03 2008-08-20 Portola Pharm Inc SUBSTITUTED ISOQUINOLEINONES
DE602004024093D1 (de) * 2003-10-03 2009-12-24 Portola Pharm Inc 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Also Published As

Publication number Publication date
JP2008514703A (ja) 2008-05-08
CN101031565A (zh) 2007-09-05
WO2006039212A2 (en) 2006-04-13
CN101031565B (zh) 2010-09-29
WO2006039212A3 (en) 2007-01-25
US20060069093A1 (en) 2006-03-30
EP1812429A2 (en) 2007-08-01
NZ554211A (en) 2010-10-29
ZA200702688B (en) 2008-06-25
KR20070064356A (ko) 2007-06-20
CA2581638A1 (en) 2006-04-13
EP1812429A4 (en) 2010-07-21
BRPI0516181A (pt) 2008-08-26
AU2005292314B2 (en) 2011-11-03
US7205296B2 (en) 2007-04-17
AU2005292314A1 (en) 2006-04-13
MX2007003836A (es) 2007-08-20
IL182180A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
HK1111414A1 (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
AP2204A (en) 4-phenylamino-quinazolin-6-yl-amides.
EG25271A (en) Fungicidal combinations.
ATE487727T1 (de) Neue 5-substituierte 7-amino-ä1,3üthiazoloä4,5- düpyrimidin-2(3h)-onderivate
AP2005003403A0 (en) Substituted pyrimidinones.
SI1897558T1 (sl) Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
SI2468732T1 (sl) 1H-kinazolin-2,4-dioni
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
PL1644343T3 (pl) Pochodne 5-podstawionego chinazolinonu
HK1107847A1 (en) Parallax-reducing, luminance-preserving diffuser
HK1063969A2 (en) Reaming aiguille.
EP1723125A4 (en) 1,2,4-benzotriazine-1,4-dioxides
GB0505823D0 (en) Boardmate, boardmate adjustable
EP1799492A4 (en) J-BACKRESTS-adjustment mechanism
IL186226A0 (en) (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
AU156894S (en) Router
ZA200502637B (en) Integrated thermostat.
PL375427A1 (pl) Wylewka, zwłaszcza hydrantowa
ZA200406832B (en) Surgical retractor assembly.
GB0419897D0 (en) T.w.e.d.s
ZA200401937B (en) Saw.
ZA200502164B (en) Geyser.
GB0405594D0 (en) E.v.o.
HK1072695A2 (en) Prefabricated part.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140926